MedTrace Logo

Study of SHR-1701 Plus BP102 in Subjects With Selected Solid Tumors

NCT04974957 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 71

Last updated 2021-07-23

No results posted yet for this study

Summary

The main purpose of this study was to assess the safety,efficacy and pharmacokinetic when combining SHR-1701 and BP102 in participants with advanced or metastatic non-squamous non-small cell lung cancer. To explore the immunogenicity of SHR-1701 and the relationship between corresponding biomarkers and therapeutic effect.

Conditions

  • Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer

Interventions

DRUG

SHR-1701；BP102

Drug: SHR-1701 IV infusion Drug: BP102 IV infusion

Sponsors & Collaborators

  • Suzhou Suncadia Biopharmaceuticals Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-30
Primary Completion
2022-02-28
Completion
2022-08-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04974957 on ClinicalTrials.gov